ZAGREB, Feb 6 (Hina) - North Croatian pharmaceutical company Belupo and Basel-based F. Hoffmann-La Roche, one of the world's leading pharmaceutical giants, earlier this year signed a general agreement on mutual cooperation.
ZAGREB, Feb 6 (Hina) - North Croatian pharmaceutical company Belupo
and Basel-based F. Hoffmann-La Roche, one of the world's leading
pharmaceutical giants, earlier this year signed a general
agreement on mutual cooperation.#L#
The agreement gives Koprivnica-based Belupo the licence to
manufacture, market, and distribute medicines from its partner's
programme. The first concrete step in cooperation refers to
"Carvedilol", a cardiovascular medicine, which Belupo has
registered under the copyrighted brand name "Carvelol".
According to a statement Belupo issued earlier in the week,
"Carvelol" acts on the heart and the cardiovascular system, is used
for high blood pressure and to treat heart conditions, and may be
found on almost every European market, as well as in the United
States.
The agreement's benefits include cuts in health costs after a
period between one and two years, the transfer of F. Hoffmann-La
Roche technology, which is expected to improve Croatia's already
high pharmaceutical standards, and in the long run the fact that
given the transfer of registration rights, "Carvelol" will become a
Croatian product owned by Belupo.
"Carvelol" has been included on the Croatian Health Insurance
Bureau list of medicines, which comes into effect on February 15,
and will be issued only on prescription. The product will also be
available in Bosnia-Herzegovina and Slovenia, and will be
manufactured in Belupo's new, DM72 million-worth, humane medicines
factory, opened last year. Manufacturing is expected to commence by
year's end.
Prior to F. Hoffmann-La Roche, Belupo signed a cooperation
agreement with Smith Kline Beecham. The newest agreement gives the
company the possibility to learn new aspects in all fields of work,
as well as to introduce the latest products.
F. Hoffmann-La Roche is the world's sixth pharmaceutical industry
in income, and among the leading in medicine manufacturing.
Operating in more than 100 countries, the company employs around
66,000 people, and annually invests around US$1.9 billion in
research and development.
(hina) ha